Live
- BGT: 'Rohit is short of confidence with self-doubts', opines Manjrekar
- Gold gains 30 pc in 2024, silver 35 pc up on COMEX this year: MOFSL
- Delhi HC dismisses anticipatory bail plea of ex-IAS trainee officer Puja Khedkar
- Untouched Goa Beaches You Must Visit in January
- Muzigal launches its State-of-the-art Music Academy in Nallagandla, Hyderabad
- Thoughtful Christmas Gifts for Every Loved One
- South Korea: Finance minister silent on martial law probe amid speculation on acting president's role
- Karnataka Minister Laxmi Hebbalkar Vows To Pursue Justice Against CT Ravi
- Stands By Vijayaraghavan Amid Row Over Remarks On Gandhis
- Karnataka Legislative Council Chairman Denies Recording Controversial Exchange
Optimus Pharma gets DCGI nod for Covid drug
Optimus Pharma gets DCGI nod for Covid drug
City-based Optimus Pharma on Tuesday received DCGI nod for conducting phase III clinical trials for orally administered Molnupiravir capsules on patients with mild and moderate Covid-19.
Hyderabad: City-based Optimus Pharma on Tuesday received DCGI nod for conducting phase III clinical trials for orally administered Molnupiravir capsules on patients with mild and moderate Covid-19. With severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.
Optimus pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI.
"Optimus is all geared to immediately begin clinical trials on Molnupiravir on Covid -19 patients in India. The clinical trial will let us know the efficacy of this molecule on Covid patients," CMD Dr D Srinivas Reddy said.
